01.03.25 -- Stage 3a: A Key Indicator For Process Validation Maturity

Learn why a strong commitment to operator training is essential to prevent production issues, ensure product quality, and safeguard patient safety.

Organoids, 3D models replicating human organs, are a growing topic of interest for researchers as they offer invaluable advantages, but come with several challenges.

Executives must take an early and active role in vetting potential partners, using a deeper understanding of the capabilities a CDMO should have to successfully bring a product to market.

Devoting early-phase resources for solid form understanding and screening during a drug’s development lifecycle is critical, as doing so can help save time and resources on the path to market.

Developing a placebo for an injectable drug requires consideration of the formulation’s impact in trials, chemistry and physical details, ethical concerns, and regulatory compliance.

Watch as industry experts walk through a variety of technologies and case studies, focusing on LPPS, peptide crystallization, method development for peptide impurity analysis, and more.

If you are in the process of developing a complex or sensitive injectable drug, learn about containment solutions to mitigate your risks and help you get your drug to the patient faster.

Explore the value of an ideal solution for manufacturing drug substances, drug products, intermediates, and other life science products—specifically designed to streamline processes and elevate quality.

This track and trace workflow illustrates the many moving parts involved in production and where two software solutions can be integrated into your systems and processes to maximize efficiency.

Here, we address a number of OHS, regulatory, and process requirements imperative to the delivery of critical containment systems.